Integrating Leading-Edge Research and Personalized Therapies to Advance Patient Care
At UH Seidman Cancer Center, our researchers conduct basic, translational, and clinical studies in many areas. Their scientific collaborations and innovations seek to optimize the delivery of standard treatments, including chemotherapy, radiation, and stem cell transplantation, and advance the development of experimental therapies. Ongoing research evaluates the clinical benefits of targeted therapy and immunotherapy in treating leukemia and other blood disorders, to better understand the mechanisms of immunotherapy resistance, explore new ways to help the body’s immune system fight cancer, and determine more effective treatment combinations.
Research Highlights
Showing of 11 results
Expansion of Wesley Center for Immunotherapy at University Hospitals Seidman Cancer Center Officially Opens
Addition brings more life-extending treatments and groundbreaking research to Northeast Ohio
New Hematology Chief and Director of the Wesley Center for Immunotherapy Named for UH Seidman Cancer Center
Koen van Besien, MD, PhD, comes to UH Seidman Cancer Center from New York-Presbyterian Hospital
UH Seidman Cancer Center to Launch First-Ever Trial of NK Therapy and Vactosertib in Treating Colorectal Cancer and Hematological Malignancies
Trial employs new method of expanding and activating universal donor NK cells developed in Cleveland - Innovations in Cancer | Winter 2022
Team Led by UH Seidman Cancer Center Researcher Develops and Validates Three-in-One CAR T Therapy
Approach detailed in the journal Nature Communications shows therapeutic potential of BAFF CAR T for treating multiple B cell cancers, using mouse models with high effectiveness and minimum side effects - Innovations in Cancer | Winter 2022
UH Seidman Cancer Center Faculty Presentation Highlights from ASH 2021 and ASTRO 2021 Annual Meetings
Innovations in Cancer | Fall 2021
Cleveland Team Develops New Method to Drive Robust Expansion and Activation of Natural Killer Cells
Approach promises to increase access to NK therapeutics - Innovations in Cancer | Fall 2021
Anti-CD19 CAR T-Cells Produced Locally at UH Seidman Cancer Center Induce High Remission Rates in B-cell Malignancies, Study Finds
Clinical trials published in Nature Communications detail advantages of local approach - Innovations in Cancer | Fall 2021